News Category
VERAXA Biotech is implementing FDA-aligned New Approach Methodologies that could reduce animal testing by up to 95% while accelerating clinical advanc...
Peptide Wholesale Supply has expanded its HPLC verification protocols to bulk orders of BPC-157, Semaglutide, and Tirzepatide, providing batch-specifi...
Telomir Pharmaceuticals' Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines at similar low concentrations, supporting further stu...
Kairos Pharma's CEO will present at a major investment conference, underscoring the company's lead candidate ENV-105, which targets CD105 to reverse d...
Quantum BioPharma's FDA clearance for a Phase 2 trial of its novel myelin repair candidate Lucid-MS marks a significant milestone that could shift the...
Nutriband's receipt of USPTO Notice of Publication for trademarks of its abuse-deterrent fentanyl patch marks progress toward commercialization, with ...
Quantum BioPharma's Lucid-MS, a potential first-in-class treatment for progressive multiple sclerosis, has garnered a 'Buy' rating from Rodman & Rensh...
Earth Science Tech's acquisition of Zoolzy LLC strategically enhances its compounding pharmacy operations, boosts profit margins, and opens new market...
Italian pharmaceutical company DuLac Farmaceutici accelerates its U.S. expansion by launching products on OneLavi and preparing for the 2026 ECRM sess...
VERAXA Biotech progresses its VXA-222 bispecific antibody-drug conjugate into preclinical validation, leveraging its proprietary technologies and expa...
Onco-Innovations Limited has signed a letter of intent to secure an exclusive option on Ifowonco's oral small-molecule LAG-3 inhibitor program, which ...
Earth Science Tech's acquisition of Zoolzy is pivotal as it enhances its pharmaceutical supply chain, reduces costs, and opens new revenue streams in ...
SCHOTT Pharma's parent group has received validation for updated climate targets, including a new Scope 3 absolute reduction target, signaling a strat...
Helus Pharma reports progress in its Phase 3 trials for HLP003, with topline data expected in Q4 2026, and advances HLP004 for generalized anxiety dis...
VERAXA Biotech's VXA-222 bispecific antibody-drug conjugate advances to the next development stage, supported by an expanded patent portfolio, undersc...
Tonix Pharmaceuticals announced FDA feedback supporting its adaptive Phase 2 field study of TNX-4800, a long-acting monoclonal antibody for Lyme disea...
VERAXA Biotech announced the advancement of its bispecific ADC program VXA-222 after OmniAb completed discovery work, moving the candidate into the ne...
VERAXA Biotech has appointed Christoph Erkel as chief scientific officer to drive the advancement of its proprietary BiTAC platform for solid tumor ca...
NanoViricides announced a $3.8 million registered direct offering with a single institutional investor, providing capital to support clinical developm...
VERAXA Biotech AG announced the appointment of Christoph Erkel as chief scientific officer, bringing two decades of antibody engineering experience to...
VERAXA Biotech AG received Scientific Advice from Germany's Paul-Ehrlich-Institute, supporting its lead BiTAC(R)-TCE program's development strategy an...
VERAXA Biotech AG announced positive regulatory feedback from Germany's Paul-Ehrlich-Institute for its BiTAC-TCE platform, advancing the program towar...
Siegfried has appointed Eduardo Montanha as COO and Executive Committee member, effective September 1, 2026, to oversee the combined Drug Substances a...
NextPlat Corp acquires an independent pharmacy near Pensacola, Florida for $1.5 million to expand its PharmcoRx retail footprint into an underserved m...
Onco-Innovations announced the completion of its analytical reference standard program for the active pharmaceutical ingredient supporting ONC010, a k...
VERAXA Biotech has partnered with ATUM to initiate cell line development for its lead BiTAC T-cell engager, a key step toward IND/CTA-enabling studies...
The sustained release polymers market is projected to grow from USD 3.8 billion in 2026 to USD 7.8 billion by 2036 at a CAGR of 7.4%, driven by rising...
VERAXA Biotech AG provided a corporate update highlighting progress in its proprietary BiTAC platform, with four T-cell engager programs targeting sol...
VERAXA Biotech has begun cell line development for its lead BiTAC T-cell engager therapy, aiming to improve tumor selectivity and reduce off-tumor tox...
The article highlights how strategic partnerships and licensing deals in antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) are creating value...
Ace Therapeutics announces end-to-end preclinical analgesic drug development services featuring a full-spectrum pain research platform with diverse in...
Medios AG is closing its Aschaffenburg facility to consolidate patient-specific manufacturing amid margin pressure from price regulations, affecting 3...
Helus Pharma announced fiscal 2026 financial results and progress on its Phase 3 trial for HLP003, a major depressive disorder treatment, with topline...
Voyageur Pharmaceuticals has hired Fluor to conduct feasibility studies for an iodine extraction facility in Oklahoma and an integrated contrast drug ...
Knight Therapeutics has fully repaid its $60 million revolving credit facility drawn to finance the Paladin acquisition, using strong operational cash...
Voyageur Pharmaceuticals is evaluating three potential U.S. sites for its integrated iodine and barium contrast media manufacturing facility, aiming t...
Earth Science Tech Inc. (ETST) has transformed into a diversified holding company with a vertically integrated telehealth and pharmacy ecosystem, emph...
Voyageur Pharmaceuticals has submitted a multi-year area-based exploration permit application for its Frances Creek barite project in British Columbia...
Voyageur Pharmaceuticals closed a $5 million private placement to fund FDA licensing for its barium contrast products and other projects, marking a ke...
Kairos Pharma's mid-year 2026 update highlights plans to acquire Phase 1-ready CL-741 for EGFR-mutated lung cancer, advance ENV-105 trials, and secure...
Quantum BioPharma's lead drug candidate Lucid-MS targets mobility loss in multiple sclerosis by addressing nerve damage, a currently unmet need, while...
Quantum BioPharma is progressing a clinical-stage multiple sclerosis program targeting demyelination, with Phase 1 safety studies completed and a plan...
Redwood AI Corp. announced DTC eligibility for its common shares, simplifying U.S. trading and enhancing liquidity, and engaged InvestorBrandNetwork f...
Carmed Pharmaceuticals, a Turkey-based company specializing in standardized carvacrol formulations, is highlighted in a CityBiz feature as it expands ...
Sino Biological's new XPressMAX™ kit enables rapid, high-throughput cell-free protein synthesis in 3 hours, supporting AI-driven antibody drug discove...
NanoViricides reported progress on its broad-spectrum antiviral NV-387, including regulatory approval for Phase II MPox trials in the DRC and FDA orph...
NanoViricides announced a $2 million registered direct offering with a single institutional investor, highlighting continued support for its broad-spe...
Lantern Pharma raised $4.4 million through a registered direct offering, with potential for additional $4.85 million from warrants, to support its AI-...
